期刊名称：ONCOTARGETS AND THERAPY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
OncoTargets and Therapy is an international, peer-reviewed journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. In terms of therapy, palliative care is also included as part of the overall patient care process. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. This journal explores the evidence behind new and existing therapies in terms of improving outcomes and, importantly, will seek to define their usage in terms of ultimate uptake and acceptance by the patient and health care professional.
Indexed online in:
PubMed (Onco Targets Ther)
EMBase
Scopus
OAIster: The Open Access Initiative
ResearchGATE scientific network
Directory of Open Access Journals (DOAJ)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Instructions to Authors
Preparation of Manuscript
Include:
Forename(s) and surnames of authors (see Authorship section below)
Author affiliations: department, institution, city, state, country
Abstract 300 words
3–6 keywords
Running header (shortened title)
Corresponding author: name, physical address, phone, fax, email
Double-spacing
3-cm margins
Page numbers
Clear concise language
American spelling
Indicate placement of tables and figures
The preferred electronic format for text is Microsoft Word
Manuscripts will be accepted in LaTeX as long as the native LaTeX and a PDF is also supplied
Use International Systems of Units (SI) symbols and recognized abbreviations for units of measurement
Do not punctuate abbreviations eg, et al, ie
Spell out acronyms in the first instance in the abstract and paper
Word counts are not specified. In general, shorter items range from 1000 to 3000 words and reviews from 3000 to 7,500
Generic drug names are used in text, tables, and figures
Suppliers of drugs, equipment, and other brand-name material are credited in parentheses (company, name, city, state, country)
If molecular sequences are used, provide a statement that the data have been deposited in a publicly accessible database, eg, GenBank, and indicate the database accession number.
While the editors fully understand the extra challenges posed to authors whose native language is not English, we must ask that all manuscripts be reviewed and edited by a native speaker of English with expertise in that area prior to submission.
Authorship
Authorship credit should be based on:
1) Substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data;
2) Drafting the article or revising it critically for important intellectual content; and
3) Final approval of the version to be published.
Authors should meet conditions 1, 2, and 3.
When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript (3). These individuals should fully meet the criteria for authorship/contributorship defined above, and editors will ask these individuals to complete journal-specific author and conflict-of-interest disclosure forms. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. The NLM indexes the group name and the names of individuals the group has identified as being directly responsible for the manuscript; it also lists the names of collaborators if they are listed in Acknowledgments.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.
All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Increasingly, authorship of multicenter trials is attributed to a group. All members of the group who are named as authors should fully meet the above criteria for authorship/contributorship.
The group should jointly make decisions about contributors/authors before submitting the manuscript for publication. The corresponding author/guarantor should be prepared to explain the presence and order of these individuals. It is not the role of editors to make authorship/contributorship decisions or to arbitrate conflicts related to authorship.
Contributors Listed in Acknowledgments
All contributors who do not meet the criteria for authorship should be listed in an acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chairperson who provided only general support. Authors should declare whether they had assistance with study design, data collection, data analysis, or manuscript preparation. If such assistance was available, the authors should disclose the identity of the individuals who provided this assistance and the entity that supported it in the published article. Financial and material support should also be acknowledged.
Groups of persons who have contributed materially to the paper but whose contributions do not justify authorship may be listed under such headings as “clinical investigators” or “participating investigators,” and their function or contribution should be described—for example, “served as scientific advisors,” “critically reviewed the study proposal,” “collected data,” or “provided and cared for study patients.” Because readers may infer their endorsement of the data and conclusions, these persons must give written permission to be acknowledged.
Please note: the Authorship and “Contributors Listed in Acknowledgments” sections are reprinted from the ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Dove Medical Press prepared this reprint. The ICMJE has not endorsed nor approved the contents of this reprint. The official version of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals is located at www.ICMJE.org. Users should cite this official version when citing the document.
Related Authors
Where authors of a paper are related this should be disclosed at the time of submission. Please provide details of the family relationship between such authors.
Figures and Tables
Submit as separate files
Number consecutively
Provide a descriptive heading/legend
Place abbreviations and footnotes immediately below the table
Use superscript a, b, c… as identifiers
Submit figures as PDFs, TIFF files, or in their originating graphics application
Supply TIFF files (Line Art 900 dpi, Combination (Line Art + Halftone) 900 dpi, Halftone 300 dpi)
Graphics downloaded from Web pages are NOT acceptable
Submit multi-panel figures, ie with parts labeled a,b,c,d, as one file
Supplementary Data
Any supplementary data should be kept to 6 typeset pages or 2,400 words. If you have any more than this you should provide a link to the supplementary data on an external website, your institute’s website for example, and/or Dove Medical Press may be able to upload the raw supplementary data to the http://www.dovepress.com/ website and provide a link in your paper. We welcome video files either as supplementary data or as part of the actual manuscript to show operations, procedures, etc.
Submission of Manuscript
All manuscripts should be submitted via our website.
By doing so you agree to the terms and conditions of submission
Keep a backup and hard copies of the material submitted
Reference Style
See Reference Style Guidelines
Proofs
You will receive the typeset page proofs for approval
Check amendments made by the editor have not rendered the material inaccurate
Check you have answered all the editor’s queries
Ensure your corrections are minimal and absolutely necessary
Mark the adjustments clearly in the text and margins, and keep a copy of what you send to the editor
Notify the editorial office of all corrections within 72 hours of your receipt of the material
Ensure all authors sign and return the Author Approval and final page of Publication Agreement
Editorial Board
Honorary Editorial Board of OncoTargets and Therapy
Editor-in-Chief: Professor Hans-Joachim Schmoll
Dr Alexiou
Christoph Alexiou, Department of Otorhinolarynglogy, Head and Neck Surgery, University Erlangen-Nürnberg, Germany
Dr Avramis
Vassilios Avramis, Department of Pediatrics, Childrens Hospital Los Angeles, Los Angeles, CA, USA
Dr Buentzel
Jens Buentzel, Chair, Department of Otolaryngology, Head Neck Oncology, Academic Hospital, Nordhausen, Germany
Dr Burdio
Fernando Burdio, Department of Surgery, Hospital del Mar, Barcelona, Spain
Dr Chamberlain
Marc Chamberlain, Professor, Neurology and Neurological Surgery, University of Washington, Seattle, Washington, USA
Dr Cho
William C. Cho, Ph.D., Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong
Dr Coll
Jean-Luc Coll, Director of Research, Institut Albert Bonniot, La Tronche, France
Dr Coskun
Uger Coskun, Department of Medical Oncology, Gazi University Medical School, Ankara, Turkey
Professor de Gramont
Aimery de Gramont, Professor, Hôpital Saint-Antoine, Paris, France
Dr Des Guetz
Gaëtan Des Guetz, Department of Medical Oncology Hôpital Avicenne, Bobigny, France
Dr Ding
George Ding, Department of Radiation Oncology, Biomedical Research Education & Training, Vanderbilt University Medical Center, Nashville, TN, USA
Professor El Saghir
Nagi Saghir, Clinical Professsor of Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Dr Farassati
Faris Farassati, Department of Medicine, The University of Kansas Medical School, KUMC-Molecular Medicine Laboratory, Kansas City, KS, USA
Professor Garcia-Carranca
Alejandro M. García-Carrancá, Professor, Molecular Biology, Unidad de Investigación Biomédica en Cáncer, Mexico City, Mexico
Professor Latreille
Jean Latreille, Oncology Department, Centre Hospitalier de l'Université de Montréal, Canada
Dr Mimeault
Murielle Mimeault, Research Associate, Department of Biochemistry and Molecular Biology, College of Medicine, Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, USA
Dr Mystakidou
Kyriaki Mystakidou, Department of Radiology, Areteion Hospital, School of Medicine, University of Athens, Greece
Professor Orel
Valeriy E.Orel, Vice President, Medical Physics and Bioengineering Department, Ukrainain Association of Medical Physics, Ukraine
Dr Oshita
Fumihiro Oshita, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Professor Pietersz
Geoffrey Pietersz, Professor, Macfarlane Institute for Medical Research, Austin Campus, Victoria, Australia
Dr Ribeiro
Marcelo Ribeiro, School of Biological and Medical Sciences, São Paulo, Brazil
Dr Rigas
James Rigas, Dartmouth Medical School, Hanover, New Hampshire, USA
Dr Romano
Gaetano Romano, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University Center for Biotechnology, hiladelphia, PA, USA
Professor Santini
Daniele Santini, Professor, Immunology and Medical Oncology, University Campus Bio-Medico, Rome, Italy
Professor Tacyildiz
Nurdan Tacyildiz, Professor, Medical School, Department of Pediatric Oncology, Ankara University, Ankara, Turkey
Professor Tan
Guang-Hong Tan, Dr, Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College, Xueyuan Lu, Haikou, Hainan (China)
Dr Teh
Bin Tean Teh, Distinguished Scientific Investigator, Van Andel Research Institute, Grand Rapids, MI, USA
Professor Tonini
Giuseppe Tonini, Professor, Director of the Oncology, Department of Medicine, Campus Bio-Medico University, Rome, Italy
Professor Tournigand
Christophe Tournigand, Professor, Hospital Saint-Antoine, Centre Hospitalier Universitaire de l'Assistance Publique des Hôpitaux de Paris, Paris, France
Dr Turturro
Francesco Turturro, Department of Medicine, LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, LA, USA
|
